Analysts expect INmune Bio to report Q3 2026 revenue of $0.00 million and a loss of $0.15 per share, with the current stock price of $1.46 significantly trailing the consensus target of $7.00.
The critical narrative for this report is the regulatory timeline for Ebstrocel's conditional approval filing with the UK MHRA, which is anticipated by the end of the year.
Investors are also seeking updates on the registrational Phase 2b/3 trial for XPro following positive imaging data in early Alzheimer's. Management's commentary on capital discipline and its $18.4 million cash position will be vital for assessing the company's runway into mid-2027.